Atai Life Sciences announced that it has invested a total of $50 million to acquire 35.5% of Beckley Psytech, which is developing BPL-003 intranasal synthetic 5-MeO-DMT (mebufotenin). Atai's subsidiary Innaris Bio is developing a gelling excipient for use in intranasal drugs for the treatment of mental health disorders. The deal includes the right of first … [Read more...] about Atai Life Sciences announces strategic investment in Beckley Psytech
Business
MannKind sells 1% royalty in Tyvaso treprostinil DPI for up to $200 million
According to MannKind Corporation, Sagard Healthcare is paying $150 million and a potential milestone payment of as much as $50 million for a 1% royalty on net sales of Tyvaso treprostinil DPI between October 1, 2023 and December 31, 2042. Tyvaso DPI is marketed by United Therapeutics, which licensed Treprostinil Technosphere from MannKind Corporation in September … [Read more...] about MannKind sells 1% royalty in Tyvaso treprostinil DPI for up to $200 million
Firebrick no longer seeking approval of Nasodine nasal spray in Australia
Firebrick Pharmaceuticals announced that it has withdrawn its appeal of a decision by the Therapeutic Goods Administration (TGA), which refused to approve the company's Nasodine povidone-iodine nasal spray as a treatment for the common cold. Firebrick said that the withdrawal was due to "the significant distraction and legal costs associated with proceeding," … [Read more...] about Firebrick no longer seeking approval of Nasodine nasal spray in Australia
Court upholds PTAB ruling invalidating United Therapeutics’ patent at center of suit delaying final approval Liquidia’s Yutrepia treprostinil DPI
According to Liquidia Corporation, the company will immediately take steps toward getting final FDA approval of Yutrepia treprostinil DPI now that the US Court of Appeals has upheld a decision by the Patent Trial and Appeal Board (PTAB) invalidating all of the claims of US Patent No. 10,716,793. Earlier this year, the Court of Appeals upheld a District Court ruling … [Read more...] about Court upholds PTAB ruling invalidating United Therapeutics’ patent at center of suit delaying final approval Liquidia’s Yutrepia treprostinil DPI
Harm Reduction announces availability of RiVive naloxone nasal spray in the US
Non-profit Harm Reduction Therapeutics (HRT) announced that it has filled the first order for RiVive naloxone nasal spray, which was approved by the FDA in July 2023 as an over-the-counter medication for the treatment of opioid overdose. RiVive, which is being manufactured by Catalent at its Morrisville, North Carolina facility, will be more available more broadly in … [Read more...] about Harm Reduction announces availability of RiVive naloxone nasal spray in the US
Vivaldi gets grant to fund preclinical transmission study of its DeltaFlu intranasal universal flu vaccine
Vivaldi Biosciences announced that the Flu Lab has provided a grant to fund a transmission study of the company's DeltaFLU intranasal universal influenza vaccine. According to the company, the study will evaluate the ability of DeltaFlu to protect against transmission of "broadly divergent wild-type influenza type A and B strains" among ferrets. The company noted … [Read more...] about Vivaldi gets grant to fund preclinical transmission study of its DeltaFlu intranasal universal flu vaccine
Favorex to market Marinomed’s Carragelose nasal spray in Thailand, Malaysia, Myanmar, and the Philippines
Marinomed Biotech announced that DKSH subsidiary Favorex has acquired commercialization rights to Marinomed's Carragelose iota-carrageenan nasal spray for Thailand, Malaysia, Myanmar, and the Philippines. Earlier this year, Carragelose nasal spray was approved in Mexico, where it will be marketed as "Barlo" by M8. Perrigo markets the nasal spray in a number of … [Read more...] about Favorex to market Marinomed’s Carragelose nasal spray in Thailand, Malaysia, Myanmar, and the Philippines
Lupin launches Vilfuro-G triple combination DPI in India
Lupin announced that the Drug Controller General of India approved the company's Vilfuro-G vilanterol / fluticasone furoate / glycopyrronium bromide dry powder inhaler for the treatment of COPD, and the company has launched the DPI in India. Earlier this year, Lupin announced the launch of its Difizma indacaterol / glycopyrronium / mometasone DPI in India for the … [Read more...] about Lupin launches Vilfuro-G triple combination DPI in India
Silo Pharma licenses Medspray’s soft mist technology for delivery of SPC-15 intranasal ketamine
Silo Pharma announced that it has signed a license agreement with Medspray Pharma for the use of Medspray's soft mist spray technology for delivery of Silo’s SPC-15 intranasal ketamine. According to Silo, the Medspray technology delivers "A formulation-specific, customized aerosol plume that is designed to allow for better deposition in the relevant region of the … [Read more...] about Silo Pharma licenses Medspray’s soft mist technology for delivery of SPC-15 intranasal ketamine
Altamira sells majority stake in Bentrio bentonite nasal spray
Altamira Therapeutics announced that a private investor has acquired a 51% stake in Altamira Medica, a subsidiary of Altamira that owns Bentrio bentonite nasal spray, which is sold over the counter for the treatment of allergic rhinitis. According to Altamira, the deal includes more than CHF 2 million (~$2.3 million) in cash, and the company will get 25% of future … [Read more...] about Altamira sells majority stake in Bentrio bentonite nasal spray